Sutro BioPharma

The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
Nasdaq triple IPO play brings in $345M as the big biotech party rocks on
Nasdaq triple IPO play brings in $345M as the big biotech party rocks on
Endpoints
NASDAQ
IPOs
Entasis
Urovant Sciences
Arvinas
Sutro BioPharma
Flag link:
Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy
Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy
Forbes
biotech
IPOs
immuno-oncology
Gritstone Oncology
Sutro BioPharma
Flag link:
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Xconomy
biotech
IPOs
Sutro BioPharma
Arvinas
cancer
Flag link:
Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline
Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline
Endpoints
Sutro BioPharma
cancer
Merck
Flag link: